Deal-Making

Healthcare-focused investment firm Altaris will snap up the advanced therapies unit, including five UK and US-based facilities, from WuXi AppTec.

Deal-Making

In addition to producing glucagon-like peptide-1 (GLP-1) drugs for an anonymous partner over five years, the Korean firm is consolidating its brands.

Facilities & Capacity

Healthcare-focused investment firm Altaris will snap up the advanced therapies unit, including five UK and US-based facilities, from WuXi AppTec.

Facilities & Capacity

As the year draws to a close, BioProcess Insider brings to you a wrap-up of the top biomanufacturing trends that shaped 2024.

Global Markets

Healthcare-focused investment firm Altaris will snap up the advanced therapies unit, including five UK and US-based facilities, from WuXi AppTec.

Regulations

The US Federal Trade Commission (FTC) has approved the acquisition of Catalent by Novo Holdings.

Regulations

The US Federal Trade Commission (FTC) has approved the acquisition of Catalent by Novo Holdings.

Regulations

Pfizer, Merck & Co., and Moderna remain upbeat over future dealings with the US government despite President-elect Trump telling vaccine-sceptic and alternative-medicine proponents to “go wild on health.”

Therapeutic Class

The agreement is expected to close by the end of 2024, expanding MilliporeSigma’s service offerings.

Therapeutic Class

The London, UK-based organization says new technologies will lead to greater efficiencies and fewer failures.

Upstream & Downstream Processing

The London, UK-based organization says new technologies will lead to greater efficiencies and fewer failures.

Facilities & Capacity

“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.